全视网膜光凝与抗血管内皮生长因子注射初始治疗增殖性糖尿病视网膜病变的比较
该回顾性队列研究利用TriNetX电子健康记录网络2003年1月至2024年1月的数据,经倾向评分匹配各1377例,比较增殖性糖尿病视网膜病变患者先接受全视网膜光凝后抗血管内皮生长因子注射与先接受抗血管内皮生长因子注射后全视网膜光凝的结局。结果显示先全视网膜光凝组5年玻璃体切割术风险更高(RR 1.88;95%CI 1.55-2.27;RD 8.93%;95%CI 6.31%-11.55%;P<.001),玻璃体积血和牵拉性视网膜脱离风险亦更高。作者认为这些发现支持需进一步研究以确定治疗顺序是否应纳入增殖性糖尿病视网膜病变的考量。
要点
- 先全视网膜光凝后抗血管内皮生长因子注射组5年玻璃体切割术风险高于先抗血管内皮生长因子注射后全视网膜光凝组(RR 1.88;95%CI 1.55-2.27)。
- 先全视网膜光凝组5年玻璃体积血风险更高(RR 1.40;95%CI 1.09-1.80;RD 6.47%;95%CI 1.66%-11.29%)。
- 先全视网膜光凝组5年牵拉性视网膜脱离风险更高(RR 1.85;95%CI 1.35-2.53;RD 4.31%;95%CI 2.10%-6.52%)。
核心结论
- 作者认为,在匹配的增殖性糖尿病视网膜病变患者中,先全视网膜光凝后抗血管内皮生长因子注射者因玻璃体积血和牵拉性视网膜脱离而接受玻璃体切割术的可能性高于先抗血管内皮生长因子注射后全视网膜光凝者。
- 作者结论指出,这些发现支持需进一步研究以确定治疗增殖性糖尿病视网膜病变时是否应考虑全视网膜光凝与抗血管内皮生长因子注射的顺序。
研究设计与样本
- 该研究为回顾性队列研究,使用TriNetX聚合电子健康记录网络2003年1月至2024年1月的数据,数据分析于2024年1月进行。
- 纳入新诊断的增殖性糖尿病视网膜病变并接受全视网膜光凝和抗血管内皮生长因子注射治疗的患者,按治疗顺序分为先全视网膜光凝后抗血管内皮生长因子注射组与先抗血管内皮生长因子注射后全视网膜光凝组。
- 倾向评分匹配前,先全视网膜光凝后抗血管内皮生长因子注射组2167例,先抗血管内皮生长因子注射后全视网膜光凝组1549例;匹配后每组各1377例。
- 匹配后队列1(先全视网膜光凝后抗血管内皮生长因子注射)平均(SD)年龄63.0(13.1)岁,队列2(先抗血管内皮生长因子注射后全视网膜光凝)平均(SD)年龄63.0(12.4)岁;队列1女性641例(46.6%),队列2女性663例(48.1%)。
主要发现
- 先全视网膜光凝后抗血管内皮生长因子注射组5年玻璃体切割术发生率高于先抗血管内皮生长因子注射后全视网膜光凝组(RR 1.88;95%CI 1.55-2.27;RD 8.93%;95%CI 6.31%-11.55%;P<.001),6个月、1年和3年时关联相似。
- 先全视网膜光凝后抗血管内皮生长因子注射组5年玻璃体积血发生率高于先抗血管内皮生长因子注射后全视网膜光凝组(RR 1.40;95%CI 1.09-1.80;RD 6.47%;95%CI 1.66%-11.29%;P<.001),6个月、1年和3年时发现相似。
- 先全视网膜光凝后抗血管内皮生长因子注射组5年牵拉性视网膜脱离发生率高于先抗血管内皮生长因子注射后全视网膜光凝组(RR 1.85;95%CI 1.35-2.53;RD 4.31%;95%CI 2.10%-6.52%;P<.001),6个月、1年和3年时发现相似。
关键数值与推荐
- 主要结局为需行玻璃体切割术,依据Current Procedural Terminology编码67040或67113定义。
- 次要结局包括玻璃体切割术、玻璃体积血或牵拉性视网膜脱离的发生率。
- 未匹配及匹配后主要结局的单因素比较均计算相对危险度、相对危险度差及95%CI。
- 匹配控制了基线人口学特征和内科合并症。
临床怎么用
- 原文结论指出,这些发现支持需进一步研究以确定治疗增殖性糖尿病视网膜病变时是否应考虑全视网膜光凝与抗血管内皮生长因子注射的顺序。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: While combined treatment of anti-vascular endothelial growth factor (VEGF) injections plus panretinal photocoagulation (PRP) is a common approach for treating proliferative diabetic retinopathy (PDR) in the clinical practice setting, large randomized clinical trials typically use monotherapy. Subsequently, information is limited as to whether the order of treatment when combining PRP and anti-VEGF injections for PDR affects outcomes. OBJECTIVE: To compare outcomes of patients with PDR treated with PRP and subsequent anti-VEGF injections with outcomes of matched patients treated with anti-VEGF injections and subsequent PRP. DESIGN, SETTING, AND PARTICIPANTS: This retrospective cohort study used data from January 2003 to January 2024 in the TriNetX aggregated electronic health records network, with data analysis performed in January 2024. Patients with PDR treated with PRP and anti-VEGF injections were eligible for inclusion. EXPOSURES: Patients with new PDR diagnoses stratified by therapy with PRP and subsequent anti-VEGF injections or anti-VEGF injections and subsequent PRP. MAIN OUTCOMES AND MEASURES: The primary outcome was the need for pars plana vitrectomy (PPV), defined by Current Procedural Terminology codes 67040 or 67113. The secondary outcome included incidence of PPV, vitreous hemorrhage (VH), or tractional retinal detachment (TRD). Relative risk ratios, relative risk differences, and 95% CIs were all calculated for univariate comparison of the cohorts and the development of primary outcomes after matching. RESULTS: Before propensity score matching (PSM), which controlled for baseline demographic characteristics and medical comorbidities, 2167 patients with PDR treated with PRP first and subsequent anti-VEGF injections and 1549 patients with PDR treated with anti-VEGF injections and subsequent PRP were included. Post-PSM, mean (SD) participant age was 63.0 (13.1) years in cohort 1 (PRP and subsequent anti-VEGF injection) and 63.0 (12.4) years in cohort 2 (anti-VEGF injection and subsequent PRP). Of 1377 total participants in each cohort, 641 patients (46.6%) and 663 patients (48.1%) in cohorts 1 and 2 were female, respectively. Treatment with PRP first and subsequent anti-VEGF injection was associated with higher rates of PPV at 5 years compared with patients treated with anti-VEGF injection and subsequent PRP (relative risk [RR], 1.88; 95% CI, 1.55-2.27; risk difference [RD], 8.93%; 95% CI, 6.31%-11.55%; P < .001), with similar associations at 6 months, 1 year, and 3 years. Treatment with PRP and subsequent anti-VEGF injection was associated with higher rates of VH at 5 years (RR, 1.40; 95% CI, 1.09-1.80; RD, 6.47%; 95% CI, 1.66%-11.29%; P < .001) and TRD at 5 years (RR, 1.85; 95% CI, 1.35-2.53; RD, 4.31%; 95% CI, 2.10%-6.52%; P < .001), with similar findings at 6 months, 1 year, and 3 years compared with patients treated with anti-VEGF injection and subsequent PRP. CONCLUSIONS AND RELEVANCE: In this retrospective cohort study, findings suggest that patients with PDR treated with PRP first then subsequent anti-VEGF injection are more likely to undergo PPV for VH and TRD compared with matched patients treated with anti-VEGF agents first, then PRP. These findings support the need for further investigations to determine if the order of PRP and anti-VEGF injections should be considered when treating patients with PDR.
引用
- Alsoudi AF, Wai KM, Koo E, et al. Initial Therapy of Panretinal Photocoagulation vs Anti-VEGF Injection for Proliferative Diabetic Retinopathy. JAMA Ophthalmol. 2024. PMID: 39207799. doi:10.1001/jamaophthalmol.2024.3283
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。